Premium
Proton pump inhibitors are not associated with inflammatory myopathies: A case control study
Author(s) -
Khoo Thomas,
Caughey Gillian E.,
Hill Catherine,
Limaye Vidya
Publication year - 2018
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.26336
Subject(s) - odds ratio , medicine , confidence interval , case control study , medical prescription , statin , diabetes mellitus , endocrinology , pharmacology
ABSTRACT Introduction : A rare association of proton pump inhibitor (PPI) use with the development of inflammatory myopathies (IM) has been reported, but, unlike with statin medications, there is limited data supporting or refuting this observation. Methods : A case‐control study was conducted on patients with IM. Clinical information, medications, and demographics were recorded. Controls were matched 3:1 for age and gender. Results : Two hundred twenty‐one cases of IM were identified. No association of PPI use with IM was observed when compared with controls (odds ratio 1.04 [95% confidence interval 0.68–1.58]) and similar results were observed after adjusting for diabetes, cardiovascular disease, and statin exposure (adjusted odds ratio 1.084 [95% confidence interval 0.69–1.70]). There was no association of any histologic subtype of IM with PPI exposure. Discussion : Our findings do not support an association of PPI exposure with IM. Co‐prescription of PPI with other medications was not considered and could be further investigated with larger cohorts. Muscle Nerve 58 :855–857, 2018